Danish healthcare company Novo Nordisk has dropped prices for its weight-loss and diabetes drug Wegoy, the injectable semaglutide, by as much as 37 per cent for its starting dose strength. The development comes on the heels of its India-partnership with Emcure Pharmaceuticals to get Wegovy to more patients across the country.
Wegovy was launched in June as a once-weekly innovative device in five dose strengths -- 0.25 mg, 0.5 mg, 1 mg, 1.7 mg & 2.4 mg.
The starting dose of Wegovy (0.25 mg) will now be available at a weekly price of ₹2,712, the company said, reflecting a 37 per cent price drop. Prices are down 20 per cent on dose strengths of 0.5 mg and 1.0 mg; down 32 per cent on 1.7 mg; and 36.9 per cent on the highest dose strength of 2.4 mg.
Vikrant Shrotriya, Managing Director, Novo Nordisk India, said: "Ever since the launch of this innovative chronic weight management medication this year, we have dedicatedly worked towards making it accessible to the maximum number of people living with overweight or obesity in India. ...Obesity is a serious concern for India, and this price revision underlines our mission to provide quality obesity treatment to Indians which is effective, safe, convenient and can be sustained in their daily lives."
In the same segment, Eli Lilly's Mounjaro had also recently tied up with Cipla to improve access to the product to more people. The anti-obesity segment is seeing much activity from innovator companies and generics, especially with a patent on Novo Nordisk's semaglutide set to expire early next year.
Comments
Published on November 11, 2025
READ MORE